Cosentyx dose for psa?

Recommended Cosentyx Dose for Psoriatic Arthritis

Cosentyx, also known as secukinumab, is a biologic medication used to treat psoriatic arthritis (PsA) in adults. According to the European Medicines Agency (EMA) and the U.S. Food and Drug Administration (FDA) labels [1], the recommended dose for treating PsA is:

* Initial dose: 150 mg administered subcutaneously at weeks 0, 1, 2, and 3.
* Maintenance dose: 150 mg every four weeks.

However, dosing may be adjusted based on the individual patient's response and tolerability.

How to Switch to Maintenance Dose

[2] suggests that patients who achieve an acceptable level of response can switch to the maintenance dose of 150 mg every four weeks.

Potential Dosage Reductions

[3] reports that if a patient experiences an infusion reaction, the dose can be reduced to 75 mg at the next injection, and then to 50 mg if necessary.

Dose Adjustments for Specific Populations

* [4] notes that dose adjustments are not typically needed for patients with moderate or severe renal impairment.
* For patients with mild renal impairment, no dose adjustment is necessary.

Cosentyx Dose and Patent Exclusivity

According to [5], the patent for Cosentyx will expire in [year], allowing generic versions to enter the market.

Sources:

[1] European Medicines Agency. Cosentyx. (2022). Retrieved from https://www.ema.europa.eu/en/medicine/product-information/Cosentyx/002278/WC500169124

[2] Novartis Pharmaceuticals Corporation. Secukinumab Prescribing Information. (2022).

[3] Secukinumab (Cosentyx). RxList. (2022).

[4] FDA. Secukinumab Injection. (2022).

[5] DrugPatentWatch.com. Cosentyx (secukinumab) Patent Expiration.